SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Aventus

Aventus ($AVT.X) is trending as community members discuss its potential, citing its low market cap, limited supply, and partnerships with Vodafone and Polkadot. Some investors believe $AVT.X could see significant gains, drawing comparisons to other low-cap coins and pointing to its potential for a breakout. Recent partnerships, including with the Truth Network, and its technology are also being highlighted as potential catalysts.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Vienna, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Strategy is trending as the stock price is not moving in sync with Bitcoin, leading to frustration among investors. The community is actively discussing whether the company's strategy of accumulating Bitcoin through debt is sustainable, especially with concerns about dilution and the stock's potential decoupling from Bitcoin's price movements. Some are speculating about potential catalysts like rate cuts or insider buying that could trigger a breakout.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending as the first U.S. spot ETF is expected to launch this week, giving it regulatory clarity and potential institutional access. The community is discussing the possible price action following the rate cut decision and anticipating a potential supply shock. Talk centers around long-term potential and the impact on global settlements.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending amidst market reactions to a recent Fed rate cut and commentary, with some traders expressing concerns about the Fed's future guidance and potential economic impacts. The community is actively discussing technical levels, potential market direction, and the influence of both economic data and political events on the ETF. Additionally, there is debate around Jimmy Kimmel's show being pulled and its implications for free speech.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid a mix of reactions to the Fed's rate cut decision and Powell's comments, with community members debating whether the market's direction reflects genuine economic optimism or a disconnect from reality. Concerns about inflation, job market uncertainties, and the potential impact of tariffs are being weighed against the backdrop of the index's strong YTD performance. Discussions also include political commentary, potential market manipulation, and individual stock picks within the broader index.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

GRRR is trending due to a newly announced $1.4 billion contract to build AI-powered data centers, sparking bullish sentiment and discussions about potential revenue impact. While some community members express excitement and anticipate a significant price increase, others are scrutinizing the details of the deal and the legitimacy of the partner company. The contract news is also fueling speculation about a potential short squeeze, compounded by upcoming events that could further boost the stock.

"What's Updog?" is a Community Led token.

UpDog

UpDog ($UPDOG.X) is trending as the community rallies around the meme-based token on the Solana network, drawing comparisons to other dog-themed coins. Discussions revolve around its potential for growth, its listing on Jupiter Exchange, and the meaning of "UpDog" itself. The community emphasizes the coin's longevity, locked liquidity, and its status as a 'joke meta pioneer.'

The Walt Disney Co. engages in the business of international family entertainment and media enterprise. It owns and operates television and radio production, distribution and broadcasting stations, direct-to-consumer services, amusement parks, and hotels. It operates through the following business segments: Disney Entertainment, ESPN, and Disney Parks, Experiences, and Products. The company was founded by Walter Elias Disney on October 16, 1923 and is headquartered in Burbank, CA.

Walt Disney Co (The)

Walt Disney Co.

$DIS is trending amid mixed reactions to recent news, including a deal with the NFL and earnings reports; the community is debating the implications of these developments, with some expressing concerns and disappointment, while others highlight the company's streaming growth and long-term potential. The stock's performance is also generating discussions around its valuation and future direction.

Bitmine Immersion Technologies, Inc. is a blockchain technology company, which engages in industrial scale digital asset mining, equipment sales, and hosting operations. It operates through the Cryptocurrency Mining Industry segment. The company was founded on August 16, 1995 and is headquartered in Las Vegas, NV.

BitMine Immersion Technologies Inc

Bitmine Immersion Technologies Inc

Bitmine Immersion Technologies is trending as its stock price moves with Ethereum, with the community actively discussing its potential to reach new heights. Bullish sentiment is fueled by the company's significant Ethereum holdings and confidence in Chairman Tom Lee. Some traders are pointing towards potential breakouts.

Solotto ($LOTTO) is the first on-chain lottery built on Solana. Holders qualify for weekly raffles by trading at least 75% of their holdings each cycle (Monday–Sunday). Wallets are split into tiers, and winners are randomly selected with prize pools funded directly from Pump.fun’s dynamic creator fees.  This system drives trading volume, rewards active participants, and gamifies the experience — giving traders both a chance to profit from market activity and to win additional rewards.  Trade. Hold. Win.

Solotto

$LOTTO.X is trending due to its unique lottery system, where a percentage of creator fees are allocated to a weekly community lottery pool, rewarding active traders and holders. Community members are excited about the potential for substantial lottery prizes and the project's growth strategy. The project leverages the Solana blockchain, with the lottery drawing occurring every Sunday.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Believe Ascendis Pharma (ASND) Could Rally 29.83%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 29.8% in Ascendis Pharma (ASND). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

U.S.-listed shares of Ascendis Pharma climbed more than 7% in Thursday’s premarket session, setting the stage for their best open since early January.Late on Wednesday, the company reported better-than-expected fourth-quarter results and announced a share repurchase program.The Danish biopharma company posted Q4 revenue of €173.92 million ($180.6 million), up from €137.7 million a year ago, while its loss per share narrowed to €0.64 from €1.53.&nbsp;CEO Jan Mikkelsen said the company is “positioned to continue strong revenue growth in 2025 and beyond,” citing Yorvipath’s early U.S. momentum and SkyTROFA’s leadership in the domestic growth hormone market.&nbsp;Ascendis also confirmed plans to submit regulatory filings for TransCon CNP as a treatment for children with achondroplasia.The board also authorized up to $18.25 million for repurchases of its American depository receipt shares.&nbsp;On Stocktwits, message volume for Ascendis spiked, with several posts indicating optimism over the guidance and Yorvipath’s growth.<stembedurl>https://stocktwits.com/Pika_Capital/message/604018998</stembedurl><stembedurl>https://stocktwits.com/CrispDry/message/603879227</stembedurl>BofA Securities on Thursday lowered its price target on Ascendis shares to $192 from $203 while maintaining a ‘Buy’ rating.&nbsp;The firm adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp, but reiterated Ascendis as a “top pick for 2025” with projected peak sales of €2.9 billion.Yorvipath recently became the only approved U.S. treatment for hypoparathyroidism after Takeda discontinued Natpara production due to supply issues.Despite the day’s gains, Ascendis shares remain down over 10% in the past year and trade about 54% below the average analyst target of $193.49, according to Koyfin data.&nbsp;&nbsp;The company’s stock has a short interest of 5.4%.(1 Euro=$1.04)For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ascendis Pharma Eyes Best Open In A Month After Q4 Print, But BofA Cuts Price Target: Retail Gets Buzzing

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.

Equity

The brokerage adjusted its 2025 Yorvipath sales forecast downward, expecting a more backloaded ramp.


Ascendis Pharma A/S (NASDAQ:ASND) Given New $167.00 Price Target at JPMorgan Chase & Co.

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) had its target price boosted by JPMorgan Chase & Co. from $165.00 to $167.00 in a research note issued to investors on Tuesday morning, Benzinga...

Ascendis Pharma A/S (NASDAQ:ASND) Given "Overweight" Rating at Cantor Fitzgerald

Cantor Fitzgerald reiterated their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in a report published on Monday morning, Benzinga reports. Cantor Fitzgerald...

Ascendis Pharma A/S (ASND, $151.98) Moving Average Convergence Divergence (MACD) Histogram turned positive on April 1, 2024

This is a Bullish indicator signaling ASND's price could rise from here. Traders may explore going long the stock or buying call options...

Ascendis Pharma A/S (ASND, $151.98) Stochastic Oscillator left the overbought zone on April 01, 2024

This is a signal that ASND's price trend could be reversing, and it may be an opportunity to sell the stock or take a defensive position...

Values First Advisors Inc. Lowers Position in Ascendis Pharma A/S (NASDAQ:ASND)

Values First Advisors Inc. reduced its stake in Ascendis Pharma A/S (NASDAQ:ASND  Free Report) by 23.4% in the fourth quarter, according to its most recent filing with the Securities and...

Ascendis Pharma A/S (ASND, $148.44) Stochastic Oscillator left the oversold zone on March 27, 2024

This is a signal that ASND's price trend could be reversing, and it may be an opportunity to buy the stock or explore call options...

1,616 Shares in Ascendis Pharma A/S (NASDAQ:ASND) Purchased by Legato Capital Management LLC

Legato Capital Management LLC purchased a new stake in Ascendis Pharma A/S (NASDAQ:ASND  Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities...

Ascendis Pharma A/S (NASDAQ:ASND) Receives Consensus Rating of "Moderate Buy" from Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND  Get Free Report) have been assigned an average rating of Moderate Buy from the ten analysts that are covering the firm, MarketBeat...

Ascendis Pharma A/S is a biopharmaceutical company, which engages in the development of drug candidates. It specializes in its TransCon technologies to develop new therapies that address unmet medical needs. The company was founded by Jan Moller Mikkelsen, Dirk Vetter, and Harald Rau on September 21, 2006 and is headquartered in Hellerup, Denmark.

Ascendis Pharma A/S - ADR

Just the one

Three

Four

The Fed just cut rates. How many cuts do you expect in all of 2025? 
 
*Powered by Polymarket

Current Price	$199.59
Prev Close	$197.24
Open	$197.96
Dividend Yield	0.00%
50-Day Moving Average	$185.79
Beta	0.66
Avg. Volume	534,417.86
PE Ratio	-39.70

52-Week High	$208.16
52-Week Low	$118.03
Market Capitalization	$11.94B
EPS (Annual)	-$7.06
Price to Book	-54.24
Revenue Per Employee	N/A
Enterprise Value/EBITDA	N/A

ASND
Ascendis Pharma

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ASND News

ASND Ascendis Pharma